### Pharmacological Actions of Hyaluronidase (LYDASE)

Hyaluronidase is an enzyme that primarily catalyzes the hydrolysis of hyaluronic acid (HA), a glycosaminoglycan in the extracellular matrix of connective tissues. LYDASE is a specific formulation of hyaluronidase derived from bovine (cattle) testes, typically available in strengths like 64 IU/mL or 1280 IU per ampoule. It acts as a "spreading factor" by depolymerizing HA, reducing its viscosity, and increasing tissue permeability. This facilitates fluid movement, drug dispersion, and resolution of tissue abnormalities. The enzyme cleaves Î²-1,4 glycosidic bonds between glucosamine and glucuronic acid in HA, leading to temporary microchannels in tissues.

Below is a comprehensive list of pharmacological actions, based on available data from clinical and pharmacological sources. For each action, I've included time-related values (e.g., onset, duration, and how it influences the action). Onset is generally immediate upon subcutaneous (SC) injection, with peak effects within minutes to hours. Duration of action is 24-48 hours due to the enzyme's high potency, despite a short half-life (2-3 minutes in plasma; <30 minutes in subcutaneous tissue). These times can vary by dose, route, and patient factors. Influences are described qualitatively, with quantitative impacts where data exists (e.g., extent of permeability increase or HA degradation).

| Pharmacological Action | Description and Influence | Time Values |
|------------------------|---------------------------|-------------|
| **Depolymerization of Hyaluronic Acid** | Breaks down HA into monosaccharides (glucosamine and glucuronic acid), reducing extracellular matrix viscosity by up to 50-90% temporarily. This creates microchannels, allowing better fluid flow and tissue remodeling. Influences: Reduces tissue resistance, aiding in scar softening and edema resolution. | Onset: Immediate (within 1-2 minutes of injection). Peak: 10-30 minutes. Duration: 24-48 hours (HA half-life is 15-20 hours naturally; enzyme extends degradation). Full tissue restoration: 48 hours. |
| **Increase in Tissue Permeability** | Enhances permeability of connective tissues and blood vessels by hydrolyzing acid mucopolysaccharides. Influences: Improves diffusion of fluids/drugs by 2-5 times the rate without hyaluronidase, reducing interstitial pressure and facilitating absorption. | Onset: Immediate. Peak: 5-15 minutes. Duration: 24-48 hours. Rate of diffusion proportional to dose (e.g., 150 IU increases spread by 3-4x in animal models). |
| **Facilitation of Drug/Fluid Absorption and Dispersion** | Acts as an adjuvant to spread injected substances (e.g., local anesthetics, contrast agents). Influences: Increases bioavailability of co-administered drugs by 20-50%, hastens onset of analgesia (e.g., reduces swelling and enhances anesthetic spread). | Onset: Immediate. Peak: 10-20 minutes. Duration: 24-48 hours. For example, with local anesthetics, onset hastened by 5-10 minutes, but systemic absorption may shorten duration by 20-30%. |
| **Reduction of Tissue Swelling (Edema)** | Decreases viscosity of interstitial fluids, promoting resorption of exudates/transudates. Influences: Reduces edema volume by 30-60% in hypodermoclysis or extravasation cases. | Onset: 5-15 minutes. Peak: 30-60 minutes. Duration: Up to 48 hours. Reported in <0.1% of cases as a side effect, but therapeutic in edema management. |
| **Scar Softening and Flattening** | Softens hypertrophic/keloid scars by breaking down HA in scar tissue. Influences: Reduces scar hardness by 20-40%, improves elasticity, and prevents contracture formation. Specific to LYDASE: Used for burn scars, ulcers, and post-surgical adhesions. | Onset: 24-48 hours per injection. Peak: After 10-20 injections (cumulative). Duration: Effects last weeks to months with repeated dosing; single dose: 24-48 hours. |
| **Improvement in Joint Mobility** | Increases range of motion in stiff joints (e.g., contractures, Dupuytren's). Influences: Enhances synovial fluid movement, reducing stiffness by 15-30% in affected joints. | Onset: 1-2 hours. Peak: 24 hours. Duration: 24-48 hours per dose; repeated for chronic conditions. |
| **Reversal of HA-Based Fillers** | Degrades cosmetic HA fillers (off-label). Influences: Dissolves fillers by 50-90% depending on dose; reverses vascular occlusion or overfilling. | Onset: Immediate (softening in minutes). Peak: 24-48 hours. Duration: Effects continue up to 48 hours; full reversal may require multiple doses. |
| **Promotion of Hematoma/Extravasation Resolution** | Aids resorption of leaked drugs/fluids (e.g., chemotherapy extravasation). Influences: Speeds clearance by 2-3x, reducing tissue damage. | Onset: 15-30 minutes. Peak: 1-2 hours. Duration: 24-48 hours. |

These actions are primarily local, with minimal systemic effects due to rapid inactivation in blood. LYDASE-specific influences include targeted use for connective tissue disorders, with effects lasting up to 48 hours SC.

### Half-Life
- Plasma half-life: 2-3 minutes (rapid deactivation by blood components).
- Subcutaneous tissue half-life: <30 minutes.
- Overall duration of action: 24-48 hours (due to high enzymatic potency and temporary HA degradation; native HA regenerates in 15-20 hours).

### Bioavailabilities by Route
Hyaluronidase is a protein enzyme, so bioavailability varies by administration route. No data supports therapeutic oral use, as proteins are degraded in the GI tract.
- **Subcutaneous (SC)**: ~100% local bioavailability; systemic exposure is negligible (<10% in animal models) due to rapid clearance.
- **Intramuscular (IM)**: Similar to SC, ~100% local, low systemic.
- **Intravenous (IV)**: 100% systemic but short-lived (half-life 2-3 minutes); not recommended for routine use due to risk of anaphylaxis.
- **Oral**: Likely 0-5% (no clinical data; enzyme degraded by proteases/peptidases in stomach/intestines; not formulated or approved for oral administration).
- **Other (e.g., intradermal, retrobulbar)**: High local bioavailability (90-100%), used off-label for specific indications like filler reversal.

### Dosages
Doses are in International Units (IU). LYDASE is typically 64 IU/mL (or 1280 IU/ampoule). General guidelines from FDA-approved uses and off-label applications; adjust for patient weight, age, and condition. Always consult product-specific labeling.

| Indication | Minimum Effective Dose | Safe Range | Maximum Without High Risks | Notes |
|------------|------------------------|------------|-----------------------------|-------|
| **Drug/Fluid Dispersion (e.g., anesthetics)** | 50 IU | 50-300 IU (typical: 150 IU added to solution) | 300 IU per injection | For SC/IM; enhances absorption without significant risks up to 300 IU. |
| **Hypodermoclysis (SC fluid admin)** | 150 IU | 150-200 IU prior to 1000 mL fluid | 200 IU | For adults; pediatric: Limit to 25 mL/kg/day (neonates) or 200 mL single clysis (<3 years). |
| **Urography (contrast resorption)** | 75 IU | 75 IU SC | 75 IU | Injected over scapula. |
| **Scar/Contracture Treatment (LYDASE-specific)** | 64 IU | 64 IU daily/every other day (10-20 injections) | 128 IU per session | SC/IM near lesion; cumulative up to 1280-2560 IU over course. |
| **Filler Reversal (off-label)** | 5-10 IU per 0.1 mL filler | 5-150 IU (nodules/Tyndall); up to 500-1500 IU for larger areas | 1500 IU (higher: 4500 IU reported safe in some cases) | Dose-dependent on filler type/volume; reassess after 24-48 hours. |
| **Extravasation Management** | 15 IU/mL (1 mL per mL extravasate) | 15-150 IU/mL solution | 150 IU per site | For vinca alkaloids; repeat if needed over 3-4 hours. |

- **Safe Range**: Generally 50-300 IU for most uses; well-tolerated in adequately hydrated patients. Pediatric: Adjust by weight (e.g., <25 mL/kg/day fluid equiv.).
- **Minimum Effective**: 5-50 IU for localized effects (e.g., small nodules); varies by filler resistance (cross-linked HA needs higher).
- **Maximum Without High Risks**: 300-1500 IU; beyond this, risk of allergy/edema increases (dose-dependent). For LYDASE, avoid exceeding 128 IU/session without monitoring.
- **LD50**: Limited human data; animal studies show low toxicity. In mice: >94 mg/kg IV (equivalent to ~140,000 IU/kg for 70kg human, far above clinical doses). In rats: No lethality at 360,000 IU/kg SC. Microbial variants: Sensitizing dose > tested clinical ranges; LD50 not reached in some studies up to 100 mg/kg.
- **When It Becomes Too Dangerous**: >1500 IU (esp. IV) risks anaphylaxis (rare, <0.1%), urticaria, angioedema, or thrombosis. Signs: Erythema, chills, hypotension. High cumulative doses (>2000 IU/course) may form neutralizing antibodies. Monitor for hypersensitivity; pretest if history of allergy. Too dangerous if patient dehydrated or has infection at site (contraindicated).